Pacific Biosciences of California, Inc. P09.F Stock
Pacific Biosciences of California, Inc. Price Chart
Pacific Biosciences of California, Inc. P09.F Financial and Trading Overview
Contents
Pacific Biosciences of California, Inc. stock price | 1.66 EUR |
Previous Close | 12.11 EUR |
Open | 11.93 EUR |
Bid | 12.04 EUR x 46100 |
Ask | 12.51 EUR x 44400 |
Day's Range | 11.93 - 11.93 EUR |
52 Week Range | 3.77 - 13.19 EUR |
Volume | 30 EUR |
Avg. Volume | 44 EUR |
Market Cap | 3.01B EUR |
Beta (5Y Monthly) | 1.668309 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.05 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 45.6 EUR |
P09.F Valuation Measures
Enterprise Value | 3.32B EUR |
Trailing P/E | N/A |
Forward P/E | -11.471154 |
PEG Ratio (5 yr expected) | 28.11 |
Price/Sales (ttm) | 22.47368 |
Price/Book (mrq) | 4.305305 |
Enterprise Value/Revenue | 24.774 |
Enterprise Value/EBITDA | -11.425 |
Trading Information
Pacific Biosciences of California, Inc. Stock Price History
Beta (5Y Monthly) | 1.668309 |
52-Week Change | 196.31% |
S&P500 52-Week Change | 20.43% |
52 Week High | 13.19 EUR |
52 Week Low | 3.77 EUR |
50-Day Moving Average | 10.69 EUR |
200-Day Moving Average | 8.82 EUR |
P09.F Share Statistics
Avg. Volume (3 month) | 44 EUR |
Avg. Daily Volume (10-Days) | 3 EUR |
Shares Outstanding | 249.89M |
Float | 229.37M |
Short Ratio | N/A |
% Held by Insiders | 1.70% |
% Held by Institutions | 86.57% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -239.32% |
Operating Margin (ttm) | -224.96% |
Gross Margin | 36.61% |
EBITDA Margin | -216.84% |
Management Effectiveness
Return on Assets (ttm) | -9.83% |
Return on Equity (ttm) | -44.96% |
Income Statement
Revenue (ttm) | 134.03M EUR |
Revenue Per Share (ttm) | 0.58 EUR |
Quarterly Revenue Growth (yoy) | 17.29% |
Gross Profit (ttm) | 53.47M EUR |
EBITDA | -290638016 EUR |
Net Income Avi to Common (ttm) | -320764000 EUR |
Diluted EPS (ttm) | -1.23 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 874.89M EUR |
Total Cash Per Share (mrq) | 3.5 EUR |
Total Debt (mrq) | 946.73M EUR |
Total Debt/Equity (mrq) | 136.79 EUR |
Current Ratio (mrq) | 3.693 |
Book Value Per Share (mrq) | 2.771 |
Cash Flow Statement
Operating Cash Flow (ttm) | -278872992 EUR |
Levered Free Cash Flow (ttm) | 39.74M EUR |
Profile of Pacific Biosciences of California, Inc.
Country | Germany |
State | CA |
City | Menlo Park |
Address | 1305 O’Brien Drive |
ZIP | 94025 |
Phone | 650 521 8000 |
Website | https://www.pacb.com |
Industry | Medical Devices |
Sector(s) | Healthcare |
Full Time Employees | 769 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Q&A For Pacific Biosciences of California, Inc. Stock
What is a current P09.F stock price?
Pacific Biosciences of California, Inc. P09.F stock price today per share is 1.66 EUR.
How to purchase Pacific Biosciences of California, Inc. stock?
You can buy P09.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pacific Biosciences of California, Inc.?
The stock symbol or ticker of Pacific Biosciences of California, Inc. is P09.F.
Which industry does the Pacific Biosciences of California, Inc. company belong to?
The Pacific Biosciences of California, Inc. industry is Medical Devices.
How many shares does Pacific Biosciences of California, Inc. have in circulation?
The max supply of Pacific Biosciences of California, Inc. shares is 282.68M.
What is Pacific Biosciences of California, Inc. Price to Earnings Ratio (PE Ratio)?
Pacific Biosciences of California, Inc. PE Ratio is now.
What was Pacific Biosciences of California, Inc. earnings per share over the trailing 12 months (TTM)?
Pacific Biosciences of California, Inc. EPS is -1.05 EUR over the trailing 12 months.
Which sector does the Pacific Biosciences of California, Inc. company belong to?
The Pacific Biosciences of California, Inc. sector is Healthcare.